Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001011438-25-000145
Filing Date
2025-02-14
Accepted
2025-02-14 09:31:31
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 9768
2 exhibit_99-1.htm EX-99.1 6416
  Complete submission text file 0001011438-25-000145.txt   18107
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX 44 1235 430000
Adaptimmune Therapeutics PLC (Subject) CIK: 0001621227 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-88833 | Film No.: 25623926
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 32 ELM PLACE, 3RD FLOOR RYE NY 10580
Business Address 32 ELM PLACE, 3RD FLOOR RYE NY 10580 917.536.6028
Two Seas Capital LP (Filed by) CIK: 0001823138 (see all company filings)

EIN.: 843799363 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G